Wells Fargo Downgrades Regeneron Pharmaceuticals (LSE:0R2M)

On May 30, 2025, Wells Fargo downgraded Regeneron Pharmaceuticals (LSE:0R2M) to Equal-Weight from Overweight, while overall fund ownership decreased by 3.30% in the last quarter to 2,377 funds. Institutional holdings also saw a slight decrease of 0.93% to 113,247K shares; major holders such as Jpmorgan Chase and Capital International Investors significantly reduced their positions by 24.76% and 18.75% respectively, although Vanguard index funds and Geode Capital Management slightly increased their holdings.

Analysis

Wells Fargo's downgrade of Regeneron Pharmaceuticals (LSE:0R2M) from Overweight to Equal-Weight on May 30, 2025, indicates a tempered analyst outlook. This development aligns with a notable shift in institutional sentiment: the number of funds reporting positions in Regeneron decreased by 81, or 3.30%, in the last quarter to 2,377. Concurrently, total shares owned by institutions experienced a slight reduction of 0.93% to 113,247K shares. Significant divestment activity is evident among major shareholders; Jpmorgan Chase reduced its holdings by 24.76% and its portfolio allocation in 0R2M by a substantial 92.61%, while Capital International Investors decreased its share ownership by 18.75% and its allocation by 21.50%. In contrast, Vanguard's Total Stock Market Index Fund and 500 Index Fund reported modest increases in share counts (0.26% and 2.51% respectively), though both funds also reduced their portfolio allocations to 0R2M by 6.87% and 6.75%. Similarly, Geode Capital Management increased its shareholding by 1.70% but cut its portfolio allocation by 51.47%. Despite these significant reductions in allocation by several key holders and the strongly negative sentiment score of -0.75 for Regeneron, the average portfolio weight of all funds dedicated to 0R2M rose by 1.74% to 0.35%, suggesting a complex dynamic where remaining or new investors might be taking slightly larger relative positions or overall fund assets have adjusted.

Key Decisions for Investors

• Investors should exercise caution and re-evaluate their exposure to Regeneron Pharmaceuticals following the Wells Fargo downgrade to Equal-Weight and observed institutional selling pressure.
• The significant reduction in holdings and portfolio allocations by major active managers like Jpmorgan Chase and Capital International Investors warrants close attention, even as some index funds marginally increased share counts.
• Monitor upcoming institutional ownership filings and analyst commentary closely for further indications of shifting sentiment or conviction regarding Regeneron's prospects, particularly in light of the current strongly negative sentiment indicators.